Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | MITF | O75030 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | JAK2 | O60674 | 2/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114421 | 0.85 | LMNA (0.69) | LMNAHSD17B10SMN1; SMN2MAPTMITF | |
| SCHEMBL11500794 | 0.83 | LMNA (0.62) | LMNAHSD17B10SMN1; SMN2MAPTMITF | |
| SCHEMBL8618054 | 0.83 | LMNA (0.67) | LMNAHSD17B10SMN1; SMN2MAPTMITF | |
| SCHEMBL13531143 | 0.82 | LMNA (0.61) | LMNAHSD17B10SMN1; SMN2MAPTMITF | |
| SCHEMBL8766911 | 0.82 | LMNA (0.61) | LMNAHSD17B10SMN1; SMN2MAPTMITF | |
| SCHEMBL845072 | 0.82 | LMNA (0.61) | LMNAHSD17B10SMN1; SMN2MAPTMITF | |
| SCHEMBL7991466 | 0.82 | LMNA (0.61) | LMNAHSD17B10SMN1; SMN2MAPTMITF | |
| SCHEMBL8767682 | 0.81 | LMNA (0.59) | LMNAHSD17B10SMN1; SMN2MAPTMITF | |
| SCHEMBL10827776 | 0.81 | LMNA (0.62) | LMNAHSD17B10SMN1; SMN2MAPTRAB9A | |
| SCHEMBL2058475 | 0.80 | GBA1 (0.61) | LMNAHSD17B10SMN1; SMN2MAPTMITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442833-B2 | Triphenylethylene compounds as selective estrogen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442833-B2 | Triphenylethylene compounds as selective estrogen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442833-B2 | Triphenylethylene compounds as selective estrogen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1692127-B1 | TRIPHENYLETHYLENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORP (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1692127-B1 | TRIPHENYLETHYLENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORP (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070111971-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-17 | — | — | US | disclosed |
| US-20070111971-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-17 | — | — | US | disclosed |
| US-20070111971-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-17 | — | — | US | disclosed |
| EP-1692127-A2 | TRIPHENYLETHYLENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005033056-A2 | TRIPHENYLETHYLENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111971-A1 | Novel compounds | GPER1, ESR2, ESR1 | LMNA 4096/4885HSD17B10 261/4885SMN1; SMN2 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.